GlobeNewswire by notified

ARTIDIS enters clinical collaboration to investigate nanomechanical profiling as a novel diagnostic and treatment optimization approach in patients with lung cancer

Share

Basel, Switzerland, May 4, 2021– ARTIDIS AG, a privately held health-tech company, announces a collaboration with Hospital Clínic de Barcelona and the University of Barcelona to investigate the ARTIDIS AFM technology as a novel diagnostictool for patients with non-small cell lung carcinoma (NSCLC), the most frequent type of lung cancer. The research partnerswill identify biomarkers that will enable fast and accurate lung cancer diagnosisin a clinical bedside setting. Based on the combinationof results from these novel nanomechanical signatures with additional patient information in the ARTIDISNet platform, a targeted and individualized treatment approachfor each patient can be identified.

In this research collaboration, ARTIDIS and teams from the University of Barcelona and Hospital Clínic de Barcelona will perform comparative analyses of nanomechanical profiles of cancer tissue and sub-cellular components, i.e. tumor microenvironments (TME), in human lung biopsies of patients with NSCLC undergoing surgery at the Hospital Clinic of Barcelona. The teams will use the proprietary ARTIDIS technology that provides nanomechanical profiling, based on atomic force microscopy of patient-derived tissues directly at the patient’s bedside, and combines it with extensive clinical information to deliver fast diagnosis and optimized treatment plans. This 18-month study aims at identifying distinct nanomechanical signatures of major histological subtypes of NSCLC as well as their genetic and immune phenotype (‘hot’ and ‘cold’ tumor). Beyond that, the study aims to show that nanomechanical profiling may be a suitable diagnostic approach in lung cancer with advantages over existing methods, including fast diagnostic assessment, increased accuracy and high specificity with a low proportion of false positives, and could contribute to an early evaluation of the expected treatment response. The results of this collaboration will have a major impact on the information available to help to select the best treatment option for lung cancer patients.

“Physicists and engineers have long used atomic force microscopy to unravel the aberrant mechanobiology of preclinical models of cancer in laboratory settings. Now we bring ARTIDIS’ exciting technology to the clinic to investigate and identify novel nanomechanical biomarkers with the ultimate goal of enabling better treatment outcomes through optimized diagnosis and more guided therapeutic selections,” said Dr. Jordi Alcaraz, Associate Professor at the School of Medicine, University of Barcelona (UB) and associate group leader at the Institute for Bioengineering of Catalonia (IBEC).

“Although the survival of cancer patients has improved thanks to the introduction of targeted therapies, we still need better tools to predict treatment response. In this collaboration, we expect to define tailor-made therapies by classifying cancer subtypes, based on nanomechanical profiles of tumor cells and their microenvironment established using atomic force microscopy, and merging these findings with the patient’s clinical data from his/her own medical history. Ultimately, we aim at providing personalized treatments for cancer patients which will hopefully contribute to better outcomes,” added Dr. Noemi Reguart, Medical Oncologist at the Hospital Clínic de Barcelona (HCB).

“Our collaboration with some of Europe’s leading research and healthcare centers will provide invaluable insight into the nanomechanical features and the treatment of NSCLC,” said Marija Plodinec, Ph.D., CEO at ARTIDIS. “It will establish nanomechanical signatures as key biomarkers in lung cancer and will allow to differentiate NSCLC subtypes and immune phenotypes. I am very excited about the perspectives our ARTIDISNet digital platform offers by combining such findings with the patient case history to establish comprehensive personal disease profiles. Our goal is to provide oncologists with a superior diagnostic approach in NSCLC that will guide patient stratification and will support them in making the best choice for successful treatment optimization for each individual patient.”

This collaboration is bringing ARTIDIS’ unique capabilities for measuring the physical aspects of biological tissue at the molecular level together with the profound expertise of the research group of Dr. Alcaraz at the UB on AFM mechanical measurements of cells and tissues, and that of the clinical group of Dr. Reguart at the HCB on the molecular analysis and diagnosis of lung cancer.

The research builds on previous ARTIDIS data, which has shown that mechanical alterations at the sub-cellular level (in nanoscale resolution) in cancer are potentially suitable markers of cancer aggressiveness and indicators for treatment response [1]. This finding was clinically validated in a prospective study in 545 breast cancer patients, where nanomechanical profiling was used to distinguish subtypes of cancerous lesions with the goal of stratifying high and low risk patients for developing metastases [2]. Moreover, ARTIDIS results suggest that nanomechanical changes in response to treatment may predict responder rate and outcome [2].

Lung cancer is one of the most common cancers and the leading cause of cancer-related death worldwide. Major reasons underlying this high mortality rate are late diagnosis and lacking methods to effectively stratify patients into distinct risk outcome groups, coupled with limited treatment options and very poor prognosis overall. The currently available diagnostic tools in lung cancer include various imaging modalities, histopathological tumor subtyping and molecular profiling of tumor biopsies. Molecular testing at the time of diagnosis also guides therapy selection, and targeted therapies in patients with several actionable genetic alterations (such as EGFR, ALK, ROS, BRAF, NTRK) are nowadays part of routine clinical management. Immunotherapy represents one of the most promising therapeutic approaches in lung cancer and evaluation of immune markers such as PD-L1 is also required at diagnosis to identify those NSCLC patients who most benefit from treatment. However, only ≤20% of lung cancer patients will respond overall underscoring the urgent need for improved methods for fast and early detection while supporting personalized treatment approaches.

References:
[1]  Plodinec, Loparic et al. Nat Nanotechnol. 2012 Nov;7(11):757-65. Link
[2]  Burian et al. AACR Annual Meeting 2020, abstract LB-273. Link

About Hospital Clínic de Barcelona
Hospital Clínic of Barcelona is a public university hospital with a centuries-long history. With 4500 employees, it is one of the leading healthcare centers in Spain and the first in scientific production. The hospital offers quality care, high-level excellence, and competitive biomedical research and a strong teaching commitment to train professionals. All of this is included in an excellent balanced management with the aim of offering society a humanized, cutting-edge medicine. www.hospitalclinic.org

About University of Barcelona
Founded in 1450, the University of Barcelona is the major public university in Catalonia and one of the most prestigious higher education institutions in Spain. The Bosch i Gimpera Foundation (FBG) is the technology transfer and innovation unit of the University of Barcelona. The FBG is responsible for transferring the results of the research carried out at the UB to society through the creation of spin-offs, patent licensing, and contracts with companies and institutions, thus contributing to the competitiveness of the business framework and the improvement of social welfare. In 2020, has developed 720 projects and contracted € 41.93 million. During the period 2018 - 2020, 51 technologies have been licensed and 8 spin-offs created. www.ub.edu

About ARTIDIS
ARTIDIS AG is a clinical stage health-tech company located in Basel, Switzerland, that has developed the first nanomechanical biomarker for cancer diagnosis and treatment optimization. The ARTIDIS nanotechnology platform integrates the mechanical biomarker data and different types of clinical data into the ARTIDISNet digital platform, allowing physicians to significantly shorten bedside biopsy analysis to less than three hours, enabling personalized disease prognosis and aiding with treatment optimization, thereby bringing benefit to both the patient and the healthcare system. Investigated initially in breast, lung, and pancreatic cancer, the ARTIDIS applications are not limited to oncology, and its nanotechnology platform can be used to analyze any kind of living tissue. For more information please visit www.artidis.com.

For further information please contact:
Dr. Marija Plodinec, CEO
Phone: +41 61 633 29 95
marija.plodinec@artidis.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Tenaris Files 2023 Annual Report on Form 20-F28.3.2024 17:47:45 CET | Press release

LUXEMBOURG, March 28, 2024 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) announces that it has filed today its Annual Report on Form 20-F for the year ended December 31, 2023, with the U.S. Securities and Exchange Commission (SEC). The annual report can be downloaded from the SEC’s website at www.sec.gov, and is available on Tenaris’s website at ir.tenaris.com. Holders of Tenaris’s shares and ADSs, and any other interested parties, may request a hard copy of the annual report, free of charge, through our website at ir.tenaris.com/tools/printed-materials. Tenaris is a leading global supplier of steel tubes and related services for the world’s energy industry and certain other industrial applications. Giovanni Sardagna Tenaris 1-888-300-5432 www.tenaris.com

International Petroleum Corporation Updated Share Capital28.3.2024 17:30:00 CET | Press release

International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) reports the following, in accordance with the Swedish Financial Instruments Trading Act: Following the cancellation of 445,000 common shares repurchased by IPC under the normal course issuer bid / share repurchase program, the total number of issued and outstanding common shares of the Corporation is 125,438,160 common shares with voting rights as at March 28, 2024 and IPC holds no common shares in treasury. International Petroleum Corp. (IPC) is an international oil and gas exploration and production company with a high quality portfolio of assets located in Canada, Malaysia and France, providing a solid foundation for organic and inorganic growth. IPC is a member of the Lundin Group of Companies. IPC is incorporated in Canada and IPC’s shares are listed on the Toronto Stock Exchange (TSX) and the Nasdaq Stockholm exchange under the symbol "IPCO". For further information, please contact: Rebecca

Subsea 7 S.A. - Seaway7 awarded contract offshore Poland28.3.2024 17:15:00 CET | Press release

Luxembourg – 28 March 2024 - Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced the award to Seaway7, part of the Subsea7 Group, of a sizeable¹ contract by PGE Polska Grupa Energetyczna and Ørsted for the transport and installation of the substations for the Baltica 2 wind farm, offshore Poland. Seaway7’s scope includes the transport and installation of four substations. Offshore activity is scheduled to take place in 2026 utilising both our heavy lift and heavy transportation vessels. Baltica 2 is a 50:50 joint venture between PGE Polska Grupa Energetyczna and Ørsted. The wind farm, with a capacity of around 1.5 GW, will be located in the Polish sector of the Baltic Sea around 40 kilometres from shore at its closest point. Maria Eidesvik, VP for Europe and US at Seaway7 said: “This is our second contract award in the emerging Polish market and we are pleased to be taking a role in developing offshore wind in this key location. With this project we also look forward to continu

Meltwater partners with leading digital agency Social Factor28.3.2024 17:00:00 CET | Press release

SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Meltwater, a leading global provider of media, social and consumer intelligence, today announces a new partnership with Social Factor, a global digital agency focusing on social CRM and strategy. With this partnership, Meltwater and Social Factor customers will be able to leverage the best of Meltwater’s social analytics and social media management solutions alongside Social Factor’s specialization in social media operations and community management. Social Factor helps enterprise-level clients turn digital chaos into human connection through content moderation, community management, analytical data, governance, training, and security. They have deep expertise working with innovative technology solutions to foster customer engagement on behalf of Fortune 500 companies and other large, global enterprises. The Meltwater social listening and social media management solutions help teams to stay on top of conversations about their company, i

International Petroleum Corp. Annual General Meeting to be held on May 8, 202428.3.2024 17:00:00 CET | Press release

International Petroleum Corporation (“IPC” or the “Corporation”) (TSX, Nasdaq Stockholm: IPCO) is pleased to announce that its Annual General Meeting (the “Meeting”) of holders of common shares (“Shareholders”) will be held at the offices of Blake, Cassels and Graydon LLP, Suite 3500, 855 - 2nd Street S.W., Calgary, Alberta, Canada T2P 4J8 on Wednesday, May 8, 2024 at 8:00 a.m. (Mountain time), for the following purposes: To receive the audited consolidated financial statements of the Corporation for the financial year ended December 31, 2023 and accompanying report of the auditor;To set the number of directors of the Corporation at eight;To elect the eight nominees of the Corporation standing for election as directors of the Corporation to hold office until the next annual meeting of Shareholders or until his or her successor is duly elected or appointed;To appoint PricewaterhouseCoopers SA, as the auditor of the Corporation, to hold office until the next annual meeting of Shareholder

HiddenA line styled icon from Orion Icon Library.Eye